Active Ingredient: Diflunisal
Diflunisal is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, 250 milligrams diflunisal, 2 times daily.
The recommended dose of diflunisal is 250 mg twice daily.
Diflunisal should be used with caution in elderly patients who are more prone to adverse reactions. No dose adjustment is required for elderly patients (≥65 years) in the absence of severe renal or hepatic insufficiency. Treatment should be reviewed at regular intervals and discontinued if no benefit is seen or intolerance occurs.
The diflunisal tablets should preferably be taken with food to reduce risk of gastro-intestinal adverse reactions.
Patients who are taking antacids should leave a 2-hour interval between taking diflunisal and taking antacid medicines.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.